Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 498 of 5804
-
A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
Disease control OngoingPatients with severe olive pollen allergy exhibit characteristic sensitization profiles, marked by strong recognition of minor allergens like Ole e 7, and, more importantly, show poor clinical responses to pharmacological treatments and immunotherapy. Previous studies have reveal…
Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New depression drug shows promise in early trial
Symptom relief Recruiting nowApimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomiz…
Phase: PHASE2 • Sponsor: Rebecca Price • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Triple-Target CAR T-Cells take on tough lymphomas
Disease control ENROLLING_BY_INVITATIONThe goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells. Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the I…
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 26, 2026 16:40 UTC
-
New daily pill shows promise for weight loss in Mid-Stage trial
Disease control OngoingThis study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants …
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New gel injection could zap liver tumors in a single visit
Disease control Recruiting nowThe goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1. Using a needle under image guidance, the liver tumor is accessed …
Phase: NA • Sponsor: inTumo Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a home device replace hospital trips for diabetic eye disease?
Disease control Recruiting nowDiabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world. Most patients with DME and vision loss require pharmacological inhibition using anti-VEGF agents with multiple monitoring visits that req…
Phase: NA • Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
20,000-Person DNA hunt aims to crack eating disorder code
Knowledge-focused Recruiting nowThe overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (B…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
AI eye on the heart: could a computer catch a rare, Often-Missed disease?
Diagnosis ENROLLING_BY_INVITATIONRecent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and accurately assess common measurements made in clinical practice. Echocardiography is the most common form of cardiac…
Phase: NA • Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New magnetic heart pump could offer hope for advanced heart failure patients
Disease control Recruiting nowThe goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Phase: NA • Sponsor: BrioHealth Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Supercharged immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation pha…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New ALS drug shows promise in Mid-Stage trial
Disease control OngoingThis study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
Phase: PHASE2 • Sponsor: Axoltis Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill could rival standard infusion for rare blood disorder
Disease control CompletedA study of the efficacy and safety of HRS-5965 capsules compared to eculizumab for 24 weeks in patients with PNH.
Phase: PHASE3 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:17 UTC
-
Promising combo aims to outsmart aggressive brain tumors in kids
Disease control OngoingThe purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tu…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could MDMA help veterans overcome PTSD? new trial explores the possibility.
Symptom relief Recruiting nowThe overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.
Phase: PHASE3 • Sponsor: Healing Breakthrough • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New hope for gallbladder cancer: chemo plus immunotherapy combo tested
Disease control Recruiting nowThis phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation), with durvalumab in treating patients who have locally advanced or metastatic gallbladder cancer. …
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental injection aims to boost Chemo's punch in aggressive breast cancer
Disease control Recruiting nowAbout 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for …
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for Hard-to-Treat prostate cancer: RS-113 under study
Disease control OngoingThe primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of diff…
Phase: PHASE2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Weight loss program may help women avoid hysterectomy and preserve fertility
Disease control Recruiting nowUp to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal wome…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for sickle cell patients: drug aims to cut painful crises
Disease control Recruiting nowA phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occ…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
Phase: PHASE1, PHASE2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC